A recent study demonstrated that FPP-3 could inhibit lipopolysaccharide-stimulated production of nitric oxide and tumor necrosis factor-a in the cultures of RAW 264.7 macrophages.
FPP-3 (10 mg/kg, p.o.) significantly suppressed the carrageen-induced paw edema in rats and, most importantly, there were no gastric ulcers formed in FPP-3-treated rats and mice, whereas indomethacin caused gastric mucosal bleeding in a dose-dependent manner. 3) In our previous studies, two metabolites were identified in rat liver cytosol and microsomal fractions in the presence of NADPH by a liquid chromatography-electrospray tandem mass spectrometry (LC/ESI-MS) and 1 H-NMR as M1, 1-furan-2-yl-3-pyridin-2-yl-propan-1-one, and M2, 1-furan-2-yl-3-pyridin-2-yl-propan-1-ol. 4) Moreover, FPP-3 and two metabolites were detected in rat sera by high-performance liquid chromatography with ultraviolet detection. 5) Further investigation on in vivo metabolism of FPP-3 was essential for the development of FPP-3 as an anti-inflammatory drug. The objective of our present study was to characterize in vivo metabolic pathway of FPP-3. The phase 1 and 2 metabolites of FPP-3 were identified by using LC/ESI-MS in male Sprague-Dawley rats.
MATERIALS AND METHODS
Materials FPP-3 (purity, Ͼ99.8%) used in this study was chemically synthesized in our group.
2) Metabolites were separated by thin layer chromatography (TLC) in our group. TLC alumina sheets (silica gel 60 F 254 ), ethyl acetate (EtOAc) and acetonitrile (ACN) were HPLC-grades from Merck Ltd. (Poole, U.K.). Formic acid was obtained from Aldrich Chemical Co. (Milwaukee, U.S.A.). All other chemicals were of analytical grade and used as received.
Animals Specific pathogen-free male Sprague-Dawley rats were obtained from Orient Co. (Seoul, Korea). The animals received at 5-6 weeks of age were acclimated for at least 1 week. Upon arrival, animals were randomized and housed 3 per cage. The animal quarters were strictly maintained at 23Ϯ3°C and 50Ϯ10% relative humidity. A 12 h light and dark cycle was used with an intensity of 150-300 lux. All animal procedures were followed based on a guideline recommended by the Society of Toxicology (Reston, VA, U.S.A.) in 1989.
Urinary and Fecal Extraction Animals were treated intravenously in penile vein with FPP-3 at 4 mg/kg in sterile saline and housed individually in metabolic cages equipped with urine and feces separators. Urine and feces from the test animals were collected and weighed at the following intervals: 0 to 12, 12 to 24 and 24 to 48 h. Four volumes of 50% ACN were added to fecal samples, followed by a homogenization. After centrifugation at 3000 g for 10 min, the supernatant was collected. The samples were stored immediately at Ϫ20°C.
For the characterization of phase 1 metabolite, the urinary and fecal samples (0.5 ml) were extracted by an addition of 1 ml of EtOAc. After mixing and centrifugation, 0.8 ml of the organic layer was separated. The organic layer was dried under a stream of nitrogen gas. A residue was reconstituted in an HPLC grade 50% ACN and injected into the LC/ESI-MS. The phase 2 metabolites were extracted by an addition of 2 volumes of ACN. After vortex mixing for 10 min and centrifugation at 13000 g at 15°C to remove the proteins, the resulting supernatant was analyzed by the LC/ESI-MS.
Biliary Excretion The bile duct was cannulated with PE10 tubing prior to dosing under ether anesthesia. The rats were treated intravenously in penile vein with FPP-3 at 4 mg/kg. Bile was collected for the first 6 h and over 6 h fol- lowing treatment, but any metabolites could not be detected in the collected bile over 6 h. Metabolites in bile samples (0.5 ml) were extracted by an addition of 1 ml of EtOAc. After mixing and centrifugation, 0.8 ml of the organic layer was separated. The organic layer was dried under a stream of nitrogen gas. A residue was reconstituted in an HPLC grade 50% ACN and injected into the LC/ESI-MS.
Enzymatic Hydrolysis of Conjugated Metabolite The urine and bile samples (0.5 ml) were incubated with b-glucuronidase (15 ml, 145 units/ml, Type H-3, Sigma Chemical Company) at 55°C for 1 h with continuous shaking. After hydrolysis, 1 ml of EtOAc was added into the sample, mixed and centrifuged, and then 0.8 ml of the organic layer was separated. The supernatants were evaporated to dryness using nitrogen gas. A residue was reconstituted in an HPLC grade 50% ACN and injected into the LC/ESI-MS.
Preparation of Cytosol Fraction The livers were perfused with phosphate-buffered saline to remove excess blood and homogenized with four volumes of ice-cold 0.1 M potassium phosphate buffer, pH 7.4. The liver homogenates were centrifuged at 9000 g for 10 min at 4°C, and the resulting post-mitochondrial supernatants were centrifuged again at 105000 g for 60 min at 4°C. The cytosol supernatants were collected and were stored at Ϫ70°C until use.
6) The contents of cytosolic protein were determined according to the method of Lowry et al. 7) using bovine serum albumin as a standard.
Preparation of Metabolites To obtain samples of standard compounds, the final concentration of FPP-3 at 3 mM was incubated with 4 mg/ml of cytosolic protein in 0.1 M potassium phosphate buffer, pH 7.4, at 37°C in a final volume of 50 ml. The reaction was initiated by the addition of an NADPH-generating system containing 0.8 mM NADPH, 10 mM glucose 6-phosphate and 1 U of glucose 6-phosphate dehydrogenase into the reaction mixture. The reaction was stopped by the addition of 100 ml EtOAc. Following mixing and centrifugation, 95 ml of the organic layer was separated and concentrated to 2 ml.
The concentrated EtOAc extracts were loaded on TLC alumina sheets. The plates were eluted with hexane : EtOAc (2 : 8). Each spot separated from the plate was extracted by EtOAc. The fractions were identified as FPP-3, M1 and M2 by LC/ESI-MS and 1 H-NMR spectra.
Determination of the Concentrations of FPP-3 and Its
Metabolites To prepare calibration standards, 5 ml of each stock solution in ACN was added to 0.5 ml drug-free urine, bile and feces. The spiked concentrations of the calibration standards were maximally 2 mg/ml of FPP-3, M1 and M2 for urine and bile and 1 mg/ml of FPP-3, M1 and M2 for feces. The samples were then processed as described in Sections of the Urinary and fecal extraction and the Biliary extraction.
LC/ESI-MS Analysis
The HPLC consisted of a surveyor system (Thermo Finnigan, San Jose, CA, U.S.A.) with the LCQ advantage trap mass spectrometer (Thermo Finnigan, San Jose, CA, U.S.A.) equipped with an electrospray ionization source. The column used for the separation was an Xterra C18 (2.1ϫ50 mm, 3.5 mm). The HPLC mobile phases consisted of 20 mM ammonium formate, pH 6.8 (A), and 100% ACN (B). A gradient program was used for the HPLC separation with a flow rate of 230 ml/min. The initial composition was 1% of B and programmed linearly to 80% of B after 8 min. Nitrogen was used as the sheath gas at 0.67 l/min with a capillary temperature of 300°C. The spray voltage set to 4.8 kV. The mass spectrometer was operated in the positive ion mode in m/z range 100-450. Helium was used as the collision gas for the tandem mass spectrometric experiments, followed by the isolation of ions over a selected mass window of 1 Da.
Statistics The mean valueϮstandard error (S.E.) was determined for each treatment group of a given experiment. Student t-test was used to compare the statistical significance of data. The significant values at either pϽ0.05 ( * ) or pϽ0.01 ( * * ) were represented as asterisks.
RESULTS

Identification of Urinary Metabolites of FPP-3
Representative extracted ion chromatograms obtained following a single intravenous injection with 4 mg/kg of FPP-3 are shown in Fig. 1 . Three different metabolites of FPP-3 were identified including one glucuronide conjugate in rat urine. The phase 1 metabolites were M1 and M2 with MH ϩ ions at m/z 202 and 204, respectively. These two metabolites were identical to the in vitro metabolites that we previously characterized following an incubation of rat liver microsomes with FPP-3 in the presence of NADPH. 5) In addition, a phase 2 metabolite was identified as the glucuronide conjugate (M3) with M2.
The MH ϩ ion of phase 2 metabolite (M3) was observed at m/z 380 in the positive ESI spectrum with a retention time of 5.1 min (Fig. 1) . The MH ϩ ions were 176 Da higher than M2,
Fig. 1. Extracted Ion Chromatograms for Phase 1 (A) and 2 (B) Metabolites of FPP-3 in Urine
A single i.v. dose of FPP-3 at 4 mg/kg was given to male SD rats. For 0-12 h following treatment, urine was collected and extracted by the method described in Materials and Methods.
indicating glucuronidation (Fig. 2) . The MS 2 spectrum of MH ϩ ion of M3 showed a major product ion at m/z 186. The MS 3 spectrum of the product ion at m/z 186 showed characterized product ions at m/z 118, 158 and 168. These product ions were identical to the MS 2 spectrum of the MH ϩ ion of M2.
5)
Identification of FPP-3 Metabolites in Bile and Feces
FPP-3, M1 and M2 were also observed in the bile in a small amount (Fig. 3) . The glucuronide conjugate (i.e., M3) could be negligibly detected in the bile (data not shown). In feces, only M2 was clearly identified (Fig. 4) . The glucuronide conjugate was not identified in the feces (data not shown).
Enzymatic Hydrolysis of Conjugated Metabolite M3 When urine and bile samples were incubated with b-glucuronidase (15 ml, 145 units/ml, Type H-3) at 55°C for 1 h, M2 was formed by the hydrolysis from M3, the glucuronide conjugate of FPP-3 (Fig. 5) . The formation of M2 by b-glucuronidase in the urine samples collected for 0-12 and 12-24 h after an i.v. dose of FPP-3 at 4 mg/kg was increased by 7.9-and 3.1-fold, respectively, when compared with the bglucuronidase-untreated controls. In addition, the production of M2 by b-glucuronidase in the bile sample collected for 0-6 h was increased by 4.2-fold, but the absolute amount produced was negligible. Meanwhile, the relative percentages of FPP-3 and M1 were not changed by the incubation of samples with b-glucuronidase.
Excretion of FPP-3 and Its Metabolites in Urine, Bile and Feces
The urinary excretion of FPP-3 and its metabolites was more preferential than the hepatic biliary excretion (Table 1) . Phase 1 metabolites were detected in neither the urine collected for 24-48 h nor the bile collected over 6 h following treatment. In addition, FPP-3 excreted into the bile was not detected in the feces in the present study.
DISCUSSION
Our recent studies indicated a possible role of NADPH-dependent reductase in the metabolism of FPP-3 in rat liver microsomes and cytosols. 4) Two phase 1 metabolites of FPP-3 such as M1 (1-furan-2-yl-3-pyridin-2-yl-propan-1-one) and M2 (1-furan-2-yl-3-pyridin-2-yl-propan-1-ol) were produced in rat liver microsome and cytosol in the presence of NADPH-generating system. Reasonable structures of two metabolites of FPP-3 could be proposed, based on the results from LC/ESI-MS and 1 H-NMR. 4) Metabolism of FPP-3 would be divided into two steps: the production of M1 from FPP-3 and the production of M2 from M1. M1 might be produced by still uncharacterized NADPH-dependent enzymes, and then M1 would be converted to M2 by carbonyl reductase or hydroxysteroid dehydrogenases (unpublished data).
Moreover, FPP-3 and its metabolites were detected at the same time in serum by using an HPLC-UV when FPP-3 was treated intravenously to male SD rats. 5) In the study, it was suggested that FPP-3 could be metabolized to M1 and M2 in vivo. In the present study, three metabolites of FPP-3 were identified including one glucuronide conjugate in rat urine (Fig. 1) . M1 and M2 identified in vitro could also be observed in the bile and feces (Figs. 3, 4) . The glucuronide conjugate (i.e., M3) of FPP-3 was identified by the loss of 194 Da consisted of glucuronic acid (176 Da) and hydroxyl group (18 Da) from the MH ϩ ion of M3 in MS 2 and by the increased production of M2 in an incubation of urine and bile with b-glucuronidase (Figs. 2, 5) . The ion at the m/z 186 was assumed to be formed by the loss of glucuronic acid and hydroxyl group as shown in Fig. 2 , because the ion at m/z 186 formed by the loss of H 2 O from the protonated M2 at m/z 204 might be more stable than the ion at m/z 204. 4, 8, 9) Glucuronidation, catalyzed by endoplasmic reticulumbound UDP-glucuronosyl-transferases, represents an important pathway for the elimination of xenobiotics and endogenous compounds in mammalians. 10) Interestingly, only a small amount of glucuronide conjugates were detected in bile in the present study. From an enzymatic hydrolysis of M3 using b-glucuronidase, it was found that M2 in urine at 0-12 h was produced almost 203-fold more than in bile at 0-6 h (Fig. 5) . These results indicated that the glucuronide conjugate of FPP-3 might be excreted into the urine predominantly. The substrate specificity of the transporters for FPP-3 would be an important factor to be concerned on this matter.
In addition, the amounts of FPP-3 and its phase 1 metabolites excreted into urine were much higher than those into bile ( Table 1) . The amounts of all compounds excreted over 12 h were less than the amounts for first 0-12 h in urine. No phase 1 metabolite was detected in the bile collected over 6 h after the administration. The results indicated that FPP-3 and its metabolites would be rapidly excreted into urine.
The total amount of metabolites excreted in urine and feces was estimated to be equivalent to approximately oneforth of administered dose. Therefore, the metabolic fate and tissue distribution of FPP-3 and its metabolites in body should be studied further to understand the biotransformation of FPP-3. Although we could not detect any other metabolites, the production of other metabolites that were not detected in the present study would be possible. Studies on these considerations are currently under investigation.
The hydrogenase (EC 1.12) might contribute to the metabolism of FPP-3 to M1, because the hydrogenases are widespread in numerous biological systems. 11) In addition, the presence of carbonyl reduction enzymes such as carbonyl reductase and hydroxysteroid dehydrogenase has been reported 970 Vol. 30, No. 5 A single i.v. dose of FPP-3 at 4 mg/kg was given to male SD rats. After treatment, urine, bile and feces were collected as described in Materials and Methods. Each value represents the meanϮS.E. of three animals. N.D., not detected. The amount of M3 was calculated from the amount of M2 produced by the treatment of individual samples with b-glucuronidase. elsewhere. 12, 13) The characteristic enzymes involved in the metabolism of FPP-3 should be investigated in the near future. In this regard, it was observed that some inhibitors of carbonyl reductase and hydroxysteroid dehydrogenase could inhibit the metabolism of FPP-3 (submitted). The possible metabolic fate of FPP-3 in rats could be proposed as summarized in Fig. 6 .
